{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Immunodeficiency+Syndrome&page=16",
    "query": {
      "condition": "Congenital Immunodeficiency Syndrome",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 425,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Immunodeficiency+Syndrome&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Congenital+Immunodeficiency+Syndrome&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T21:17:31.929Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06549114",
      "title": "Leniolisib for Immune Dysregulation in PIDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency Disorders (PIDs)"
      ],
      "interventions": [
        {
          "name": "Leniolisib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 13,
      "start_date": "2024-10-21",
      "completion_date": "2026-06-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06549114"
    },
    {
      "nct_id": "NCT06876363",
      "title": "Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "X-Linked Chronic Granulomatous Disease"
      ],
      "interventions": [
        {
          "name": "EN-374",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Ensoma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "3 Months and older · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2025-08-05",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Francisco, California • St. Petersburg, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06876363"
    },
    {
      "nct_id": "NCT00055341",
      "title": "Treatment of Hepatitis C in Hemophilic Patients With HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis C",
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2002-03",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2008-07-30",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00055341"
    },
    {
      "nct_id": "NCT00468273",
      "title": "A Clinical Study of Intravenous Immunoglobulin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Immunologic Deficiency Syndromes"
      ],
      "interventions": [
        {
          "name": "Immune Globulin Intravenous (Human) Omr-IgG-am IGIV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FFF Enterprises",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "3 Years to 75 Years"
      },
      "enrollment_count": 57,
      "start_date": "2006-11",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2014-08-11",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Centennial, Colorado • North Palm Beach, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00468273"
    },
    {
      "nct_id": "NCT00002251",
      "title": "A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cytomegalovirus Infections",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "13 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002251"
    },
    {
      "nct_id": "NCT03907241",
      "title": "CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunodeficiency"
      ],
      "interventions": [
        {
          "name": "Octanorm 16.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 27,
      "start_date": "2016-03-01",
      "completion_date": "2019-09-05",
      "has_results": true,
      "last_update_posted_date": "2020-10-27",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 6,
      "location_summary": "Irvine, California • San Diego, California • Centennial, Colorado + 3 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Papillion",
          "state": "Nebraska"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907241"
    },
    {
      "nct_id": "NCT04429568",
      "title": "THC Crossover Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "THC",
        "Cannabis",
        "Cannabis Smoking",
        "Cannabis Use, Unspecified",
        "Cigarette Smoking",
        "Tobacco Use",
        "Nicotine Dependence",
        "Nicotine Withdrawal",
        "Cardiovascular Risk Factor"
      ],
      "interventions": [
        {
          "name": "Smoked Cannabis",
          "type": "OTHER"
        },
        {
          "name": "Vaped Cannabis",
          "type": "OTHER"
        },
        {
          "name": "Tobacco Cigarette",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-10-30",
      "completion_date": "2024-06-25",
      "has_results": false,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 2,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04429568"
    },
    {
      "nct_id": "NCT03266653",
      "title": "EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epstein-Barr Virus Infections",
        "Primary Immune Deficiency Disorder"
      ],
      "interventions": [
        {
          "name": "cytotoxic t-lymphocytes",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "1 Month to 79 Years"
      },
      "enrollment_count": 20,
      "start_date": "2020-07-07",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03266653"
    },
    {
      "nct_id": "NCT02247739",
      "title": "A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Recombinant human C1 inhibitor",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2014-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-12-08",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 4,
      "location_summary": "Tampa, Florida • St Louis, Missouri • Lake Oswego, Oregon",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Lake Oswego",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02247739"
    },
    {
      "nct_id": "NCT04691622",
      "title": "Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Viral Infection",
        "Hematopoietic Stem Cell Transplantation (HSCT)",
        "Primary Immunodeficiency Disorders (PID)"
      ],
      "interventions": [
        {
          "name": "Norovirus -specific T-cell (NST) therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's National Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "3 Months to 80 Years"
      },
      "enrollment_count": 48,
      "start_date": "2022-03-17",
      "completion_date": "2028-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-10-24T21:17:31.929Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04691622"
    }
  ]
}